[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myasthenia-gravis-associated-with-thymoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myasthenia-gravis-associated-with-thymoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100636887","thymic-disease-autoimmunity-and-neuromuscular-junction-integrity-in-myasthenia-gravis-100636887",false,"NCT07571525","Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis","Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis: An Observational Prospective Translational Cohort Study","TAILOR-MG","Inclusion Criteria:\n\n* Age ≥18 years at the time of informed consent\n* Ability to provide written informed consent and comply with study procedures\n* Availability of a serum sample for testing MG-related antibodies\n* Availability of chest imaging (CT and\u002For MRI) to classify thymic status\n\nParticipants must also meet the criteria for at least one of the following study groups:\n\nCohort 1: Thymoma with MG-related antibodies\n\n* Histologically or radiologically confirmed thymoma\n* Presence of at least one pathogenic MG-related antibody (AChR)\n* Presence or absence of clinically manifest myasthenia gravis\n\nCohort 2: Other thymic abnormalities with MG-related antibodies\n\n* Imaging or histological evidence of non-thymomatous thymic pathology (e.g., thymic hyperplasia)\n* Presence of at least one pathogenic MG-related antibody (AChR)\n* Presence or absence of clinically manifest myasthenia gravis\n\nCohort 3: Thymoma without MG-related antibodies\n\n* Histologically or radiologically confirmed thymoma\n* Negative for pathogenic MG-related antibodies (AChR)\n* No clinical diagnosis or symptoms suggestive of myasthenia gravis\n\nCohort 4: Myasthenia gravis without thymic abnormalities\n\n* Established clinical diagnosis of myasthenia gravis with consistent clinical features, supported by at least one of the following:\n\n  1. Seropositivity for MG-related antibodies (AChR, MuSK, or LRP4), or\n  2. Abnormal neuromuscular transmission demonstrated by SFEMG or RNS, or\n  3. Improvement of MG signs with treatment such as oral acetylcholinesterase inhibitors, plasma exchange, IVIg, or corticosteroids\n* Absence of thymic abnormalities on CT or MRI\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Other neuromuscular diseases that could interfere with interpretation of clinical or neurophysiological findings\n* Severe uncontrolled systemic illness that, in the investigator's judgment, may limit participation or confound study outcomes\n* Any medical or psychiatric condition, or history of substance abuse, that may compromise adherence to study procedures\n* Pregnancy or breastfeeding","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to investigate the clinical, immunological, and neuromuscular features associated with the development and progression of myasthenia gravis (MG) in adult patients with thymic abnormalities and\u002For MG-related antibodies, including individuals with or without clinically manifest disease.\n\nThe main questions it aims to answer are:\n\n* Whether integrated clinical, serological, and histopathological profiles are associated with the presence of MG and can predict disease onset or progression\n* Wheter systemic immune markers are associated with disease activity, progression, and neuromuscular junction alterations\n\nParticipants will:\n\n* Undergo clinical, neurological, and neurophysiological assessments at baseline and during follow-up\n* Provide blood samples for serological and immunological analyses\n* Provide thymic tissue and residual intercostal muscle samples (when undergoing clinically indicated thymectomy) for research analyses\n* Attend follow-up visits at 6, 12, and 18 months\n* Record daily symptoms using an electronic patient-reported outcome tool (for participants with MG)",[25,26,27],"Myasthenia Gravis (MG)","Myasthenia Gravis Associated With Thymoma","Thymoma",[29,30],"myasthenia gravis","thymoma","NOT_YET_RECRUITING","2026-04-30",{"date":34,"type":35},"2026-05-06","ACTUAL",{"date":37,"type":21},"2026-09-15",{"date":39,"type":21},"2029-12-01",{"name":41,"class":42},"IRCCS San Raffaele","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":43},"100610741","phase-3-efg-vs-ivig-in-tamg-100610741","NCT07231523","EFG vs IVIG in TAMG","Perioperative Efficacy and Safety of Efgartigimod Versus Intravenous Immunoglobulin for Thymoma Associated Myasthenia Gravis: a Prospective, Multicenter, Randomized Controlled Study","Inclusion Criteria:\n\n1. Patients aged \\>18 years and ≤75 years, with an expected survival time \\>12 months;\n2. Patients with generalized myasthenia gravis;\n3. MG-ADL ≥6;\n4. Positive for AChR antibody;\n5. Diagnosed with thymoma by enhanced chest CT or MRI;\n6. Patients with thymoma combined with myasthenia gravis who are diagnosed by MDT and need to undergo thymectomy;\n7. Patients with American Society of Anesthesiologists (ASA) grade 1-2;\n8. Able to understand the study situation and sign the Informed Consent.\n\nExclusion Criteria:\n\n1. MGFA type V;\n2. Patients who have undergone median sternotomy;\n3. Confirmed history of congestive heart failure; poorly controlled angina pectoris with drug treatment; electrocardiogram (ECG) confirmed transmural myocardial infarction; poorly controlled hypertension; clinically significant valvular heart disease; or high-risk uncontrolled arrhythmia;\n4. Patients with weight loss of more than 5kg in the past month; severe uncontrolled systemic disease, such as active infection or poorly controlled diabetes; patients with hemorrhagic diseases and bleeding tendencies; coagulation dysfunction, bleeding tendency or receiving thrombolytic or anticoagulant therapy; patients with grade II-IV bone marrow suppression;\n5. Females with positive serum pregnancy test or in lactation period, and males and females of childbearing age who are unwilling to use adequate contraceptive measures during treatment;\n6. History of organ transplantation (including autologous bone marrow transplantation and peripheral stem cell transplantation);\n7. Patients with peripheral nervous system disorders or significant mental disorders and a history of central nervous system disorders;\n8. Patients participating in other clinical studies simultaneously;\n9. Patients who cannot tolerate single-lung ventilation during surgery; severe cardiac complications, cardiovascular decompensation, patients with implanted cardiac pacemakers;\n10. Patients in the acute inflammatory period due to bacterial, viral or other microbial infections; known active infections of human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV), or known HIV seropositivity;\n11. Patients who have undergone thoracic surgery due to tuberculous pleurisy, mesothelioma, lung disease, or diaphragmatic disease, with ipsilateral lung atelectasis involving one lobe or more than one lobe;\n12. Serum IgG level \\\u003C4.5 g\u002FL;\n13. Received biological agents such as rituximab or ibritumomab tiuxetan within 6 months; underwent plasma exchange within 1 month;\n14. Thrombosis, renal impairment or renal failure;\n15. Allergic to human immunoglobulin or have other severe allergic history;\n16. Selective IgA deficiency with anti-IgA antibodies;\n17. Subjects with impaired function of major organs, abnormal blood routine, lung, liver, kidney and cardiac function, and the following laboratory test results:\n\nBlood: white blood cells \\\u003C4.0×10\\^9\u002FL, absolute neutrophil count (ANC) \\\u003C2.0×10\\^9\u002FL, platelet count \\\u003C100×10\\^9\u002FL, hemoglobin \\\u003C90g\u002FL; Liver function: serum bilirubin \\>1.5 times the upper normal limit; ALT and AST \\>1.5 times the upper normal limit; Renal function: serum creatinine (SCr) \\>120 μmol\u002FL, creatinine clearance rate (CCr) \\\u003C60 ml\u002Fmin;","75 Years",{"count":53,"type":21},64,"INTERVENTIONAL",[56],"PHASE3","This study is a prospective, multi-center, randomized controlled study to evaluate the efficacy and safety of efgartigimod (EFG) and intravenous immunoglobulin (IVIG) in the perioperative application for acetylcholine receptor (AChR) antibody-positive thymoma patients with myasthenia gravis in order to provide reliable evidence for clinical decision-making.",[59,60,26],"Efgartigimod","Intravenous Immunoglobulin","2025-11-14",{"date":63,"type":35},"2025-11-17",{"date":65,"type":21},"2025-12-01",{"date":67,"type":21},"2027-12-01",{"name":69,"class":42},"Shanghai Zhongshan Hospital",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":79,"studyType":22,"phases":4,"briefSummary":80,"conditions":81,"keywords":95,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":43},"100563559","myasthenia-gravis-foundation-of-america-global-mg-patient-registry-100563559","NCT06617741","Myasthenia Gravis Foundation of America Global MG Patient Registry","MGFAPR","Inclusion Criteria:\n\n* age over 18\n* positive MG diagnosis\n\nExclusion Criteria:\n\n* age under 18\n* misdiagnosed with MG",{"count":78,"type":21},3800,"15 Years","The goal of this observational study is to learn about the experiences of people living with Myasthenia Gravis (MG) in the United States. The main questions it aims to answer are:\n\n* How and when are people with MG diagnosed?\n* What are the most common symptoms associated with MG?\n* What treatments are being used to treat MG?\n* What are the impacts of MG on activities of daily living, employment and quality of life?\n* What are the experiences with exacerbation, hospitalization and healthcare access for people with MG? Participants will answer a survey to enroll in the study, and be invited to fill out an update survey twice a year.",[82,83,84,85,86,87,88,89,90,91,92,93,94],"Myasthaenia Gravis","Myasthenia","Myasthenia Gravis Associated with Thymoma","Myasthenia Gravis Crisis","Myasthenia Gravis Exacerbations","Myasthenia Gravis Generalised","Myasthenia Gravis with Exacerbation (Disorder)","Myasthenia Gravis, Adult Form","Myasthenia Gravis, Generalized","Myasthenia Gravis, Ocular","Myasthenia Gravis, Thymectomy","Myasthenia Gravis","Myasthenia Gravis, MuSK",[96,97,98,99,29],"myasthenia","patient registry","MGFA","Myasthenia Gravis Foundation of America","RECRUITING","2024-09-26",{"date":103,"type":35},"2024-09-27",{"date":105,"type":35},"2013-10-12",{"date":107,"type":21},"2029-09-19",{"name":99,"class":42}]